Rizvi joins KSQ TODAY as CEO and will also become a member of the company's board of directors.
Rizvi is a healthcare executive with broad experience in the biopharmaceuticals industry and was most recently senior vice president of operations and chief commercial officer at Kiniksa Pharmaceuticals.
Prior to joining KSQ, Rizvi was senior vice president of operations and chief commercial officer at Kiniksa Pharmaceuticals.
He held previous positions at Genentech, where he most recently served as vice president and franchise head of Tecentriq, with commercial responsibilities for Genentech's cancer immunotherapy portfolio.
Earlier, he led Roche's hematology franchise, as VP of global product strategy and lifecycle leader for Hemlibra for hemophilia A. Dr. Rizvi has a record of success in building exceptional teams that deliver results.
He has extensive launch experience in the oncology space; having launched Herceptin, Perjeta and Kadcyla for HER2-positive breast cancer as well as Venclexta for chronic lymphocytic leukemia and Gazyva for follicular lymphoma.
Under his leadership, Rituxan Hycela received FDA approval as the first sub-cutaneous treatment for non-Hodgkin's lymphoma.
Prior to joining Genentech, Dr. Rizvi was at Novo Nordisk and Eli Lilly, where he served in numerous roles in sales, marketing, business development and new product planning.
Rizvi earned an MB.ChB. from the University of Dundee Medical School in Scotland. He completed his residency in general surgery, including rotations in neurosurgery, orthopedics, ENT and accident and emergency care. He also holds an M.B.A. from the Ross School of Business at the University of Michigan.
KSQ Therapeutics is advancing a pipeline of tumor- and immune-focused drug candidates for the treatment of cancer across multiple drug modalities including targeted therapies, adoptive cell therapies and immuno-therapies.
KSQ's proprietary CRISPRomics discovery engine enables genome-scale, in vivo validated, unbiased drug discovery across broad therapeutic areas. KSQ was founded by thought leaders in the field of functional genomics and pioneers of CRISPR screening technologies.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval